DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-2.66%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.09B
AUM Growth
+$3.09B
(+16%)
Cap. Flow
+$741M
Cap. Flow
% of AUM
24.01%
Top 10 Holdings %
Top 10 Hldgs %
53.08%
Holding
78
New
16
Increased
25
Reduced
8
Closed
8
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$96.7M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$79.4M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$76.2M |
| 4 |
Akero Therapeutics
AKRO
|
$69.6M |
| 5 |
BridgeBio Pharma
BBIO
|
$68.5M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$125M |
| 2 |
Harmony Biosciences
HRMY
|
$49.9M |
| 3 |
Neumora Therapeutics
NMRA
|
$42.4M |
| 4 |
Genmab
GMAB
|
$41.7M |
| 5 |
Guardant Health
GH
|
$41.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Xenon Pharmaceuticals
XENE
$2.99B
| $33.6M | 1.09% |
1,000,000
+830,868
| +491% | +$27.9M |
|
27
Edgewise Therapeutics
EWTX
$1.54B
| $30.8M | 1% |
1,400,000
+689,579
| +97% | +$15.2M |
|
|
MTSR
28
Metsera, Inc. Common Stock
MTSR
$3.75B
| $29.8M | 0.96% |
+1,094,408
| New | +$29.8M |
|
29
Vaxcyte
PCVX
$4.17B
| $28.3M | 0.92% |
+750,000
| New | +$28.3M |
|
|
AUTL
30
Autolus Therapeutics
AUTL
$383M
| $27.7M | 0.9% |
17,849,482
+3,630,579
| +26% | +$5.63M |
|
|
BCAX
31
Bicara Therapeutics Inc. Common Stock
BCAX
$655M
| $26.1M | 0.84% |
2,000,000
| – | – |
|
|
CMPS
32
Compass Pathways
CMPS
$452M
| $25.3M | 0.82% |
+8,859,648
| New | +$25.3M |
|
|
TECX
33
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $24.8M | 0.8% |
+1,401,938
| New | +$24.8M |
|
|
ABVX
34
Abivax
ABVX
$6.2B
| $22.4M | 0.72% |
3,579,209
| – | – |
|
|
MBX
35
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $22.3M | 0.72% |
3,018,935
| – | – |
|
36
GH Research
GHRS
$870M
| $22.1M | 0.71% |
+2,000,000
| New | +$22.1M |
|
37
Dyne Therapeutics
DYN
$1.92B
| $20.9M | 0.68% |
2,000,000
| – | – |
|
38
enGene Holdings
ENGN
$249M
| $20.4M | 0.66% |
4,557,575
| – | – |
|
39
Insmed
INSM
$30.3B
| $19.4M | 0.63% |
+254,751
| New | +$19.4M |
|
40
Galapagos
GLPG
$2.06B
| $18.6M | 0.6% |
741,068
-39,710
| -5% | -$998K |
|
|
SAGE
41
DELISTED
Sage Therapeutics
SAGE
| $16.2M | 0.52% |
+2,038,845
| New | +$16.2M |
|
42
Terns Pharmaceuticals
TERN
$651M
| $15.4M | 0.5% |
5,576,558
| – | – |
|
43
Korro Bio
KRRO
$244M
| $15.2M | 0.49% |
874,614
| – | – |
|
|
ORKA
44
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $14.8M | 0.48% |
1,444,709
+694,709
| +93% | +$7.13M |
|
45
MindMed
MNMD
$689M
| $14.6M | 0.47% |
2,500,000
-316,594
| -11% | -$1.85M |
|
|
UPB
46
Upstream Bio, Inc. Common Stock
UPB
$1.08B
| $14.1M | 0.46% |
2,299,567
+1,299,567
| +130% | +$7.95M |
|
47
Olema Pharmaceuticals
OLMA
$432M
| $12.9M | 0.42% |
3,442,833
| – | – |
|
|
SEPN
48
Septerna, Inc. Common Stock
SEPN
$628M
| $11.1M | 0.36% |
1,912,929
| – | – |
|
49
Novavax
NVAX
$1.2B
| $9.73M | 0.32% |
1,518,182
-481,818
| -24% | -$3.09M |
|
|
CYBN
50
Cybin
CYBN
$142M
| $9.7M | 0.31% |
1,529,987
| – | – |
|